Friday, 24 April 2015

Diffusion tensor MR tractography effective as quantitative tool, treatment marker response

Preliminary results of a study of patients with prostate cancer show that MR tractography may be a reliable quantitative imaging biomarker to assess prostate cancer treatment response to androgen deprivation and radiation therapy, according to a team of researchers at Brigham and Women's Hospital and Massachusetts General Hospital in Boston. Quantitative evaluation shows higher tract densities after androgen deprivation and radiation therapy, reflecting gland shrinkage and subsequent fibrosis.

Twenty-two patients with elevated prostate-specific antigen and biopsy-proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with endorectal coil were divided into two groups: those who were treated with , , or both, and a Gleason-matched control group who had not received such therapy.

"Diffusion tensor MR tractography may function as a novel quantitative tool and marker of treatment response," said study coauthor Jennifer W. Uyeda, MD, Brigham and Women's Hospital. "For example, absence of rise in tract density after therapy and persistent or wider gradient can signify poor response."

The study was presented at the ARRS 2015 Annual Meeting in Toronto.

More information: View the abstract.

Medical Xpress on facebook

Related Stories

Reasearcher recommends wider use of androgen-deprivation therapy for high PSA levels

date Jun 13, 2014

Men whose prostate-specific antigen (PSA) level increases after radical prostatectomy or radiotherapy but who have no known metastases comprise the second-largest group of patients with prostate cancer. However, no standard ...

Noninvasive assay monitored treatment response in patients with metastatic prostate cancer

date Oct 23, 2012

Deciding the ideal treatment for patients with metastatic prostate cancer that stops responding to initial therapy could be guided by certain analyses of cancer cells isolated from the patients' blood, according to data published ...

Androgen deprivation therapy has lasting impact on function

date Mar 31, 2015

(HealthDay)—For patients with prostate cancer, androgen deprivation therapy (ADT) has a lasting impact on physical function, according to a study published online March 24 in Cancer.

Ultrasound/MRI fusion biopsy detects more sonographically occult prostate cancers

date Apr 20, 2015

Research conducted at the State University of New York Upstate Medical University has found that multiparametric MRI and subsequent fusion of MR images with ultrasound enables a targeted biopsy of high-suspicion foci with ...

Primary androgen deprivation therapy ineffective for most men with early prostate cancer

date Mar 17, 2014

A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received ...

Recommended for you

Researchers test treatment that can halt acute myeloid leukemia

date 30 minutes ago

Acute myeloid leukemia is a conundrum among cancers. Immature cells swamp the bone marrow, crowd out healthy cells, and all too often can have devastating consequences.

Self-reported health predicts survival in breast cancer

date 1 hour ago

(HealthDay)—For older women with breast cancer, low self-rated health (SRH) and limited walking ability predict worse all-cause survival at five and 10 years, according to a study published in the April ...

DBT dramatically improves cancer detection rate in dense breast tissue

date 2 hours ago

Digital breast tomosynthesis (DBT) increases the rate of cancer detection in women with dense breast tissue by as much as 67%, according to new research from the Einstein Medical Center in Philadelphia.

Cures and curcumin: Turmeric offers potential therapy for oral cancers

date 7 hours ago

Turmeric—the familiar yellow spice common in Indian and Asian cooking—may play a therapeutic role in oral cancers associated with human papillomavirus, according to new research published in ecancermedicalscience.

Novel therapeutic candidate targets key driver of HCC in genomically defined subset of patients

date 7 hours ago

Findings were presented today at The International Liver Congress 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor ...

Stem-cell-based therapy promising for treatment of breast cancer metastases in the brain

date 10 hours ago

Investigators from Massachusetts General Hospital (MGH) and the Harvard Stem Cell Institute have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here

to reset your password.

Sign in to get notified via email when new comments are made.



Categories:

0 comments:

Post a Comment